Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults

Ítems similars

• Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01
  per: Huang, Yunda, et al.
  Publicat: (2020)
• Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
  per: Ledgerwood, J E, et al.
  Publicat: (2015)
• Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01
  per: Li, Yuxing, et al.
  Publicat: (2011)
• Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants
  per: Cunningham, Coleen K, et al.
  Publicat: (2020)
• Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
  per: Mayer, Kenneth H., et al.
  Publicat: (2017)